Atika Capital Management’s Moderna MRNA Stock Holding History

Atika Capital Management’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-10,000	Closed	-$153K	–	86
2018 Q4	$153K	Buy	+10,000	New	+$164K	0.05%	70

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Atika Capital Management's MRNA Position: Q1 2019 in Review

Atika Capital Management sold out of Moderna (MRNA) in Q1 2019, closing a stake of 10,000 shares — an estimated $153K sold.

Atika Capital Management first reported a position in MRNA in Q4 2018 and held it in 1 quarter. The position peaked at $153K in Q4 2018. 106 funds tracked by Wall St. Rank hold MRNA as of Q1 2019.

Atika Capital Management reported no remaining Moderna position as of Q1 2019 after selling out during the quarter.
Atika Capital Management sold 10,000 Moderna shares in Q1 2019, an estimated $153K.
Atika Capital Management first reported a position in Moderna in Q4 2018 and held it in 1 quarter.
Atika Capital Management's Moderna position peaked at $153K in Q4 2018.
106 funds tracked by Wall St. Rank held Moderna as of Q1 2019.

Based on Atika Capital Management's 13F filing for Q1 2019, filed 13 May 2019.